Parisa Khajuee
Bronx, NYNPI 1952648842
Payments from drug & device makers
Across 249 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$821
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$527
- Lundbeck LLC$362
- Vanda Pharmaceuticals Inc.$348
- Lilly USA, LLC$342
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $1,545 |
| Otsuka America Pharmaceutical, Inc. | 54 | $821 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $527 |
| Lundbeck LLC | 18 | $362 |
| Vanda Pharmaceuticals Inc. | 21 | $348 |
| Lilly USA, LLC | 26 | $342 |
| Pfizer | 16 | $325 |
| Kyowa Kirin, Inc. | 14 | $310 |
| Teva Pharmaceuticals USA, Inc. | 7 | $164 |
| Idorsia Pharmaceuticals US Inc | 4 | $82 |
| Eisai Inc. | 3 | $60 |
| SK Life Science, Inc. | 2 | $58 |
| Alkermes, Inc. | 2 | $53 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Novartis | 2 | $44 |
| Vertex | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| MDD US Operations, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Life Molecular Imaging Ltd | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 25 | $44,676 |
| Nurtec OdtRimegepant Sulfate | 32 | $41,037 |
| UbrelvyUbrogepant | 21 | $36,636 |
| RytaryCarbidopa/Levodopa | 17 | $16,801 |
| QuliptaAtogepant | 12 | $15,750 |
| Memantine Hcl | 307 | $3,896 |
| Pregabalin | 17 | $964 |
| Nortriptyline Hcl | 129 | $871 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 54 | $748 |
| Duloxetine Hcl | 14 | $543 |
| Bupropion XlBupropion Hcl | 16 | $487 |
| Divalproex Sodium | 60 | $450 |
| Mirtazapine | 37 | $432 |
| Primidone | 27 | $404 |
| Gabapentin | 78 | $340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,545 | $52,38633 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $821 | $44,67625 claims |
| PfizerNurtec Odt | $325 | $41,03732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.